Navigation Links
Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use
Date:1/14/2008

SEATTLE Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers at Fred Hutchinson Cancer Research Center.

Previous research indicated that five or more years of combined hormone-therapy use was necessary to increase overall breast-cancer risk, said Christopher I. Li, M.D., Ph.D., the lead author of the report, published in the January issue of Cancer Epidemiology, Biomarkers and Prevention. Our study, the first specifically designed to evaluate the relationship between combined HRT and lobular breast cancers, suggests that a significantly shorter length of exposure to such hormones may confer an increased risk.

The study, which confirms previous reports of the association between combined hormone-therapy use and increased risk of lobular breast cancers, is the largest study of combined HRT and lobular cancer risk in the United States. It is also the first such study to take into account the recency and duration of hormone use and the first to include a centralized pathological review of tumor specimens to confirm their histological type: ductal, lobular or mixed ductal-lobular.

Lobular cancer involves the lobules, or chambers, in the breast that contain milk-producing glands. While lobular carcinoma accounts for only about 15 percent of all invasive breast cancers, it is hormonally sensitive and therefore more treatable than the more common ductal variety, which arises in the ducts that carry milk from the lobules to the nipple. However, lobular breast tumors also present a clinical challenge because they are more difficult to detect both by clinical examination and by mammography than ductal cancers, which account for about 70 percent of invasive breast cancers in the United States.

The study assessed hormone-replacement status in more than 1,500 postmenopausal women in western Washington 1,044 breast-cancer cases (324 lobular, 196 mixed ductal-lobular and 524 ductal) and 469 controls. The researchers also confirmed tumor status through centralized examination of breast tissue.

The researchers found that current users of combined HRT had a 2.7-fold and 3.3-fold elevated risk of lobular and ductal-lobular cancer, respectively, regardless of tumor stage, size or number of lymph nodes involved. Only women who used combined HRT for three or more years faced an increased risk of lobular cancer. Among mixed ductal-lobular cases, hormone therapy increased the risk of tumors that were predominantly lobular but not tumors that had predominantly ductal characteristics.

The incidence of invasive lobular and ductal-lobular breast cancers has risen rapidly in the United States, increasing 52 percent and 96 percent, respectively, between 1987 and 1999, whereas rates of ductal cancer have increased only 3 percent during this time.

Our research suggests that the use of postmenopausal hormone-replacement therapy, specifically the use of combined estrogen-plus-progestin preparations, may be contributing to this increase, said Li, an associate member of the Hutchinson Centers Public Health Sciences Division.

While the number of postmenopausal women taking combined HRT long-term has dropped by about half in recent years due to Womens Health Initiative reports of health risks associated with such therapy, such as an increase in heart-disease and breast-cancer risk, a substantial number of women are still taking HRT to manage the symptoms of menopause.

These findings are still of considerable public-health importance considering the estimated 57 million prescriptions for menopausal hormone therapy that continue to be filled in the United States, Li said.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
2. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
3. Combined Boards Provide Better Care to More Clients More Efficiently
4. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
5. Fat on chest and upper back increases risk of insulin resistance
6. Handling Stress Properly Increases Good Cholesterol
7. High alcohol consumption increases stroke risk among Chinese men
8. High alcohol consumption increases stroke risk, Tulane study says
9. Genetic predisposition increases childhood asthma risk
10. Smoking increases risks for head and neck cancers for men and women
11. Passive smoking increases sleep disturbance among pregnant women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , ... January 23, 2017 , ... ... coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is ... CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who love ...
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, ... the world’s largest start-up platform headquartered in Silicon Valley that connects startups to ... Ventures recently signed a three-year agreement to be a corporate sponsor of Plug ...
(Date:1/24/2017)... , ... January 23, 2017 , ... The January 2017 ... a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as ... and interpersonal difficulties while experiencing an increased sense of purpose both during and after ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... analyzed statistics from 140 Buzzies users who entered metrics into the product’s app. ... clinical data. The new data showed that within just 30 seconds of using ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... new plugin that allows sleep centers to automatically connect and initialize all their ... thin client browser plugin is quickly installed on first use and then monitors ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Research, titled, "Acidity Regulators Market - Global Opportunity Analysis ... regulators was valued at $4,456 million in 2015, and is expected ... 7.96% from 2016 to 2022. Asia-Pacific generated ... lead, followed by North America and ...
(Date:1/24/2017)... SEOUL, Korea , Jan. 24, 2017 ... Reddy,s in New Jersey State court alleging that Dr. ... deficiencies in its Food and Drug Administration (FDA) cGMP ... notes that Dr. Reddy,s repeatedly represented to Mezzion that ... hid its misconduct from Mezzion.  The suit also states ...
Breaking Medicine Technology: